Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the MCRN ‐003/ MYX .1 single arm phase II trial-Reference-Cited by-同舟云学术

Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the MCRN ‐003/ MYX .1 single arm phase II trial

Published:2021-04-12 Issue:5 Volume:96 Page:552-560
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Venner Christopher P.¹^ORCID,LeBlanc Richard²,Sandhu Irwindeep¹,White Darrell³,Belch Andrew R.¹^ORCID,Reece Donna E.⁴,Chen Christine⁴,Dolan Sean⁵,Lalancette Marc⁶,Louzada Martha⁷,Kew Andrea⁸,McCurdy Arleigh⁸,Monteith Bethany⁹,Reiman Tony⁵,McDonald Gail⁹,Sherry Max⁹,Gul Engin¹⁰,Chen Bingshu E.⁹,Hay Annette E.⁹

Affiliation:

1. The Cross Cancer Institute University of Alberta Edmonton Alberta Canada

2. CIUSSS de lʼEst de lʼIle de Montréal Université de Montréal Montreal Quebec Canada

3. Queen Elizabeth II Health Sciences Centre Dalhousie University Halifax Nova Scotia Canada

4. Princess Margaret Cancer Centre Toronto Ontario Canada

5. University of New Brunswick Saint John Regional Hospital Saint John New Brunswick Canada

6. Hotel Dieu Hospital Quebec City Quebec Canada

7. London Regional Cancer Centre University of Western Ontario London Ontario Canada

8. The Ottawa Hospital University of Ottawa Ottawa Ontario Canada

9. Queenʼs University Canadian Cancer Trials Group Kingston Ontario Canada

10. Canadian Myeloma Research Group (formerly the Myeloma Canada Research Network) Vaughan Ontario Canada

Funder

Amgen Canada

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.26147

Reference40 articles.

1. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients;Kumar SK;Leukemia,2014

2. Novel agents improve survival of transplant patients with multiple myeloma including those with high‐risk disease defined by early relapse (<12 months);Venner CP;Leuk Lymphoma,2011

3. The evolving impact on survival outcomes in multiple myeloma with greater access to novel treatment regimens: experience in a real‐world cohort;Breckenridge ZM;Blood,2017

4. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study;Kumar SK;Leukemia,2011

5. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma;Dimopoulos MA;N Engl J Med,2016

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Updates on Therapeutic Strategies in the Treatment of Relapsed/Refractory Multiple Myeloma;Cancers;2024-08-23

2. Green tea extract improves cyclophosphamide-induced immunosuppression in mouse spleen and enhances the immune activity of RAW 264.7 cells;Heliyon;2023-11

3. A Meta-Analysis of the Efficacy of Pomalidomide-Based Regimens for the Treatment of Relapsed/Refractory Multiple Myeloma After Lenalidomide Exposure;Clinical Lymphoma Myeloma and Leukemia;2023-11

4. Alpha-lipoic acid supplementation reverses the declining quality of oocytes exposed to cyclophosphamide;Food and Chemical Toxicology;2023-11

5. Revisiting the role of alkylating agents in multiple myeloma: Up-to-date evidence and future perspectives;Critical Reviews in Oncology/Hematology;2023-07